Ownership and insider activity for OS Therapies Incorporated (OSTX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
Price
| Price | $1.75 |
| Market Cap | $80M |
| Exchange | AMEX |
| Country | US |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.23B | $80788 | $171480 | $38982 | $5.5M | $269830 |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $430.5M | $231071 | $1145 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $1.68B | $312815 | $496835 | $790032 | $5.5M | $332912 |
| Property, Plant & Equipment | $1.9M | $13076 | $12270 | $8050 | $5270 | $2490 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | $6.5M |
| Total Assets | $1.68B | $325891 | $509105 | $798082 | $5.5M | $6.8M |
| Accounts Payable | $40000 | $856521 | $1.2M | $2.7M | $1.7M | $9.9M |
| Short-term Debt | $871.2M | 0 | 0 | $14.6M | 0 | 0 |
| Total Current Liabilities | $2.10B | $3.5M | $6.1M | $24.7M | $4.6M | $11.8M |
| Long-term Debt | $5.90B | $7.1M | $10.3M | 0 | 0 | 0 |
| Total Liabilities | $8.00B | $11.8M | $18.1M | $24.8M | $4.7M | $12.9M |
| Retained Earnings | -$6.34B | -$15.2M | -$21.6M | -$29.5M | -$40.4M | -$67.2M |
| Total Equity | -$6.33B | -$11.5M | -$17.6M | -$24.0M | $811487 | -$6.1M |
| Total Debt | $6.77B | $7.1M | $10.3M | $14.6M | 0 | 0 |
| Net Debt | $5.54B | $7.0M | $10.2M | $14.6M | -$5.5M | -$269830 |
| Working Capital | -$427.1M | -$3.2M | -$5.7M | -$23.9M | $906217 | -$11.4M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 0.18 |
Profitability
| Return on Equity | 683.03% |
| Return on Invested Capital | 350.07% |
| Return on Assets | -397.78% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADAG · COEP · CRVO · EQ · HOWL · INKT · IOBT
Explore sector: Healthcare · Biotechnology
More sections of OSTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks